Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Circulating Tumor DNA Response Adapted Treatment De-escalation Metastatic Urothelial Carcinoma (CT-READ)

NCT07183319 is registered in ClinicalTrials.gov with University of Oklahoma as lead sponsor.

NCT NCT07183319
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07183319 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Circulating Tumor DNA Response Adapted Treatment De-escalation Metastatic Urothelial Carcinoma (CT-READ)
Lead sponsor
University of Oklahoma
Phase
Phase 2
Overall status
Recruiting
Start date
January 19, 2026
Completion date
March 31, 2029
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

urothelial carcinoma